Ivana Magovčević-Liebisch

KIFFIK Biomedical

Reginald Swift

KIFFIK Biomedical has appointed Reginald Swift as fractional Chief Scientific Officer. Swift is the founder and CEO of Rubix LS, as well as the co-founder, CEO and CSO of TheraSyn Bio. He also holds advisory roles at companies such as Manglovo Health, Music Beats Cancer, The Lawrence Partnership and inGen Dynamics.

KIFFIK Biomedical

Rene Veloso

KIFFIK Biomedical has appointed Rene Veloso as Chief Investment Officer. Veloso’s most recent role was as Senior Vice President at Locust Walk Partners; prior to this, he served as Senior Executive: Corporate Development and Business Advisory at DLA Piper and Senior Vice President of Business and Corporate Development at Bellwether Behavioural Health.

Richmond Pharmacology

Edward Jackson

Richmond Pharmacology has appointed Edward Jackson as Medical Director. Jackson joined Richmond in 2021, following six years at the NHS as a junior doctor and junior clinical fellow. His previous roles at Richmond include Lead Speciality Research Physician and Associate Medical Director. He has also served as Associate Medical Director at Owlstone Medical.

Richmond Pharmacology

Priscilla Ochuba

Richmond Pharmacology has appointed Priscilla Ochuba as Associate Medical Director. Ochuba joined Richmond in 2022, and previously served as Lead Research Physician and Senior Research Physician. Prior to joining Richmond, she held the role of Senior House Officer at King’s College Hospital and worked as a medical doctor in Bradford and Airedale.

ARTBIO

Julie O’Neill

ARTBIO has appointed Julie O’Neill to its board of directors. O’Neill is chair of the National Institute for Bioprocessing Research and Training, and previously served as Executive Vice President, Global Operations at Alexion Pharmaceuticals. Other roles include Non Executive Director at ICON and DBV Technologies and Non Executive Board Member at Advancion Sciences.

ARTBIO

Maha Katabi

ARTBIO has appointed Maha Katabi to its board of directors. Katabi brings more than 20 years’ experience in leadership and investments. She has been a General Partner at Sofinnova Investments since 2020 and has also served as a Board Member at companies including Marea Therapeutics, Star Therapeutics, Quanta Therapeutics and Vera Therapeutics.

BioDuro

Christopher Conway

BioDuro has appointed Christopher Conway to its board of directors. Conway, the current CEO of Bio X Cell, brings over 25 years of experience in life sciences to the role. His previous roles include over a decade at Curia, where he served as President, and Board Member at DCAT and Viyash Life Sciences.

Neogap Therapeutics

Jonas Mattsson

Neogap Therapeutics has appointed Jonas Mattsson to its board of directors. Mattsson holds the roles of Director and Professor at the Princess Margaret Cancer Centre and the University of Toronto. He was previously a physician for almost 25 years at Karolinska University Hospital and a senior physician at Oslo University Hospital.